CytoDyn Company Profile (NASDAQ:CYDY)

About CytoDyn (NASDAQ:CYDY)

CytoDyn logoCytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company's lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells. The Company's product pipeline also includes Cytolin and CytoFeline. Cytolin is a mouse monoclonal antibody developed to identify a specific type of immune cell called a cytotoxic T cell, or cytotoxic T lymphocyte (CTL). CytoFeline is an anti-lymphocyte function-associated antigen-1 (LFA-1) antibody for the treatment of Feline Immunodeficiency Virus (FIV) infection. PRO 140 blocks HIV from entering a cell by binding to a molecule called C-C chemokine receptor type 5 (CCR5). The Company has finished Phase II clinical trials for PRO 140 with demonstrated antiviral activity in man.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CYDY
  • CUSIP: N/A
  • Web: www.cytodyn.com/
Capitalization:
  • Market Cap: $99.9 million
  • Outstanding Shares: 152,763,000
Average Prices:
  • 50 Day Moving Avg: $0.65
  • 200 Day Moving Avg: $0.65
  • 52 Week Range: $0.46 - $0.84
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.76
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: ($0.05) per share
  • Price / Book: -12.80
Profitability:
  • EBITDA: ($31,420,000.00)
  • Return on Equity: -1,270.12%
  • Return on Assets: -240.16%
Misc:
  • Average Volume: 117,451 shs.
 

Frequently Asked Questions for CytoDyn (NASDAQ:CYDY)

What is CytoDyn's stock symbol?

CytoDyn trades on the NASDAQ under the ticker symbol "CYDY."

How were CytoDyn's earnings last quarter?

CytoDyn Inc (NASDAQ:CYDY) posted its earnings results on Tuesday, October, 10th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.05) by $0.03. View CytoDyn's Earnings History.

When will CytoDyn make its next earnings announcement?

CytoDyn is scheduled to release their next quarterly earnings announcement on Friday, January, 12th 2018. View Earnings Estimates for CytoDyn.

Where is CytoDyn's stock going? Where will CytoDyn's stock price be in 2017?

1 analysts have issued 1-year price objectives for CytoDyn's stock. Their predictions range from $2.00 to $2.00. On average, they expect CytoDyn's stock price to reach $2.00 in the next twelve months. View Analyst Ratings for CytoDyn.

Who are some of CytoDyn's key competitors?

Who are CytoDyn's key executives?

CytoDyn's management team includes the folowing people:

  • Anthony D. Caracciolo, Independent Chairman of the Board
  • Nader Z. Pourhassan Ph.D., President, Chief Executive Officer, Director
  • Michael D. Mulholland, Chief Financial Officer, Treasurer, Corporate Secretary
  • Denis R. Burger Ph.D., Director
  • Carl C. Dockery, Director
  • Gregory A. Gould CPA, Independent Director
  • A. Bruce Montgomery M.D., Independent Director
  • Jordan G. Naydenov, Independent Director

How do I buy CytoDyn stock?

Shares of CytoDyn can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CytoDyn's stock price today?

One share of CytoDyn stock can currently be purchased for approximately $0.64.


MarketBeat Community Rating for CytoDyn (NASDAQ CYDY)
Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  39 (Vote Outperform)
Underperform Votes:  48 (Vote Underperform)
Total Votes:  87
MarketBeat's community ratings are surveys of what our community members think about CytoDyn and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for CytoDyn (NASDAQ:CYDY) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $2.00 (212.50% upside)
Consensus Price Target History for CytoDyn (NASDAQ:CYDY)
Price Target History for CytoDyn (NASDAQ:CYDY)
Analysts' Ratings History for CytoDyn (NASDAQ:CYDY)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/10/2017HC WainwrightSet Price TargetBuy$2.00LowView Rating Details
10/6/2016Rodman & RenshawInitiated CoverageBuy$1.60N/AView Rating Details
(Data available from 10/20/2015 forward)

Earnings

Earnings History for CytoDyn (NASDAQ:CYDY)
Earnings by Quarter for CytoDyn (NASDAQ:CYDY)
Earnings History by Quarter for CytoDyn (NASDAQ CYDY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/12/2018        
10/10/2017Q1 2018($0.05)($0.08)ViewN/AView Earnings Details
10/12/2016Q1($0.05)($0.04)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for CytoDyn (NASDAQ:CYDY)
Current Year EPS Consensus Estimate: $-0.17 EPS
Next Year EPS Consensus Estimate: $-0.17 EPS

Dividends

Dividend History for CytoDyn (NASDAQ:CYDY)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for CytoDyn (NASDAQ:CYDY)
Insider Trades by Quarter for CytoDyn (NASDAQ:CYDY)
Insider Trades by Quarter for CytoDyn (NASDAQ:CYDY)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/21/2016Nader PourhassanInsiderBuy15,000$0.66$9,900.00View SEC Filing  
10/17/2016Michael D MulhollandCFOBuy11,000$0.66$7,260.00View SEC Filing  
10/30/2014Anthony CaraccioloDirectorBuy26,000$0.72$18,720.00View SEC Filing  
10/15/2014Michael D MulhollandCFOBuy2,500$0.79$1,975.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for CytoDyn (NASDAQ:CYDY)
Latest Headlines for CytoDyn (NASDAQ:CYDY)
Source:
DateHeadline
seekingalpha.com logoCytoDyn Dresses HIV Patients In CCR5 Halloween 'Mask'
seekingalpha.com - October 20 at 7:11 PM
finance.yahoo.com logoCytoDyn Announces Investment Community Conference Call for October 19, 2017
finance.yahoo.com - October 17 at 6:29 PM
globenewswire.com logoCytoDyn Provides Update on PRO 140 Combination Therapy Pivotal Trial in HIV Patients Following Constructive ... - GlobeNewswire (press release)
globenewswire.com - October 15 at 3:36 AM
americanbankingnews.com logoZacks: Analysts Anticipate CytoDyn Inc (CYDY) to Post -$0.05 Earnings Per Share
www.americanbankingnews.com - October 14 at 6:06 AM
finance.yahoo.com logoCytoDyn Provides Update on PRO 140 Combination Therapy Pivotal Trial in HIV Patients Following Constructive Meeting With FDA
finance.yahoo.com - October 13 at 6:15 PM
americanbankingnews.com logoCytoDyn Inc (CYDY) Announces Earnings Results
www.americanbankingnews.com - October 11 at 8:48 AM
streetinsider.com logoCytodyn, Inc. (CYDY) Granted FDA Orphan Drug Designation for PRO 140 - StreetInsider.com
www.streetinsider.com - October 7 at 3:22 PM
finance.yahoo.com logoCytoDyn Receives Orphan Drug Designation for PRO 140 for Prevention of Graft Versus Host Disease
finance.yahoo.com - October 5 at 10:36 AM
nasdaq.com logoCytoDyn to Present at the Rodman & Renshaw 19th Annual Global Investment Conference - Nasdaq
www.nasdaq.com - September 7 at 10:48 PM
finance.yahoo.com logoCytoDyn to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
finance.yahoo.com - September 7 at 5:47 PM
nasdaq.com logoCytoDyn Provides Further Update on PRO 140 Pivotal Combination Therapy Trial in Patients with HIV - Nasdaq
www.nasdaq.com - September 6 at 10:45 PM
finance.yahoo.com logoCytoDyn Provides Further Update on PRO 140 Pivotal Combination Therapy Trial in Patients with HIV
finance.yahoo.com - September 6 at 5:42 PM
globenewswire.com logoCytoDyn Provides Update on PRO 140 Pivotal Combination Therapy Trial in Patients with HIV - GlobeNewswire (press release)
globenewswire.com - August 21 at 5:26 PM
finance.yahoo.com logoCytoDyn Provides Update on PRO 140 Pivotal Combination Therapy Trial in Patients with HIV
finance.yahoo.com - August 21 at 5:26 PM
globenewswire.com logoCytoDyn Provides Update on Enrollment in its Pivotal Phase 2b/3 HIV Combination Trial - GlobeNewswire (press release)
globenewswire.com - August 9 at 5:55 PM
finance.yahoo.com logoCytoDyn Provides Update on Enrollment in its Pivotal Phase 2b/3 HIV Combination Trial
finance.yahoo.com - August 9 at 5:55 PM
americanbankingnews.com logo CytoDyn Inc (NASDAQ:CYDY) Receives Average Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - August 9 at 7:10 AM
americanbankingnews.com logo Analysts Set $2.88 Price Target for CytoDyn Inc (NASDAQ:CYDY)
www.americanbankingnews.com - July 19 at 6:28 PM
americanbankingnews.com logo Analysts Expect CytoDyn Inc (CYDY) Will Post Earnings of -$0.05 Per Share
www.americanbankingnews.com - July 7 at 8:22 PM
feeds.benzinga.com logoCytoDyn to Present an Update on its PRO 140 Pivotal Phase 2b/3 Study in Treatment-Experienced HIV-1 Patients at ASM Microbe 2017
feeds.benzinga.com - June 1 at 6:53 AM
globenewswire.com logoCytoDyn Treats First Patient with PRO 140 in Phase 2 Trial for Graft versus Host Disease - GlobeNewswire (press release)
globenewswire.com - May 17 at 11:18 AM
seekingalpha.com logoCytoDyn's (CYDY) CEO Nader Pourhassan Hosts Investment Community Conference Call (Transcript)
seekingalpha.com - April 19 at 12:36 PM
globenewswire.com logoCytoDyn Announces Investment Community Conference Call for April 18, 2017 - GlobeNewswire (press release)
globenewswire.com - April 8 at 10:15 AM
prnewswire.com logoSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating CytoDyn Inc. for Potential Breaches Of Fiduciary ... - PR Newswire (press release)
www.prnewswire.com - April 3 at 5:02 PM
biz.yahoo.com logoCYTODYN INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - March 30 at 5:02 PM
feeds.benzinga.com logoData Presented at CROI Show CytoDyn's Pro 140 as a Single Agent Provided Maximal Virologic Suppression in HIV Patients for Nearly Two Years
feeds.benzinga.com - February 16 at 12:26 AM
biz.yahoo.com logoCYTODYN INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits
biz.yahoo.com - December 12 at 12:09 PM

Social

Chart

CytoDyn (CYDY) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.